What you need to know
• The interventions of highest value for people with chronic obstructive pulmonary disease (COPD) are treatment and support to stop smoking, pulmonary rehabilitation in patients limited by breathlessness, and flu vaccination
• Choice of initial long acting inhaled therapies depends on the presence or absence of asthmatic features/features which suggest steroid responsiveness
• Self management plans improve quality of life and reduce hospital admissions
• Treatment for acute exacerbations of COPD, including rescue packs for patients to use for self management, should be for five days only
• Only prescribe home oxygen for people who are hypoxic and do not smoke currently
There are 1.3 million people in the UK with a diagnosis of chronic obstructive pulmonary disease (COPD) and the condition is responsible for considerable morbidity and mortality. 1 COPD is also a common cause of hospital admission. NHS England has now recognised respiratory disease as a priority area in the Long Term Plan, 2 but Royal College of Physicians COPD Audits 3 identify substantial deficiencies across the healthcare system, including marked under-provision of pulmonary rehabilitation, flu vaccination, and smoking cessation treatment.
This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE). 10 The updated areas are mainly concerned with the management of stable COPD and include self management and education, assessment for lung volume reduction procedures, and home oxygen use. This article focuses on the newly updated sections, with reference to older recommendations where they are particularly important or needed for context.
Effective COPD management pathways require an integrated approach across primary and secondary care and involve a multidisciplinary team of health professionals. The guidance focuses on the need to ensure that good quality care is delivered wherever patients are seen. Specialist care, whether delivered in a hospital or community setting, may be indicated for people with COPD onset at a young age or those with rapidly progressive disease, frequent exacerbations, multimorbidity, hypoxia, or for assessment for a lung volume reduction procedure.
What's new in the guidance?
• A new one page algorithm focuses on the "Five Fundamentals" of COPD care as a "desktop" guide for clinicians, including an explicit reference to the importance of multimorbidity 
Diagnosis
The guideline still recommends considering a possible diagnosis of COPD in anyone with breathlessness, cough, or chronic sputum production, with risk factors including a history of tobacco smoking or work in an occupation with exposure to dust, fumes, or chemicals. Diagnosis depends on the presence of airflow obstruction which is not reversible, measured using spirometry. A FEV 1 /FVC ratio of <0.7 is usually taken to indicate airflow obstruction, though this fixed level may overdiagnose older people and underdiagnose younger people, so correlation with other clinical symptoms and signs is important.
The use of composite scores to guide prognosis in COPD is no longer recommended. Instead, consider individual risk factors that influence long term prognosis (box 1). • Carbon monoxide gas transfer (TLco)
• Meeting criteria for long term oxygen therapy and/or home non-invasive ventilation
• Multimorbidity
• Frailty
Incidental findings of lung abnormalities on imaging are an increasingly common way for people with COPD to present. New recommendations suggest that these findings should prompt a primary care respiratory review to identify the presence of symptoms, perform spirometry, and offer treatment and support to stop smoking where appropriate.
Fundamentals of COPD care
As part of the update process a new algorithm was developed that covered non-pharmacological management of COPD and the use of inhaled therapies ( fig 1) . As part of this process, the most important interventions or treatments were identified and grouped as the "five fundamentals" of COPD care, based on their high value in terms of clinical and cost effectiveness 4 (box 2). 
Patient education and self management
The new guideline stresses the importance of providing information about COPD at multiple points (box 3). Pulmonary rehabilitation programmes, which should be offered to all patients with COPD who are limited by breathlessness, are an important way of delivering help to enable patients to understand how to manage their condition.
Box 3: COPD patient information
At diagnosis and at each review appointment, offer people with COPD and their family members or carers (as appropriate)
• written information about their condition
• opportunities for discussion with a healthcare professional who has experience in caring for people with COPD.
Written information should meet the NHS accessible information standard (eg, British Lung Foundation COPD materials https://www.blf.org.uk/supportfor-you/copd).
Minimum required information
• an explanation of COPD and its symptoms • details of local and national organisations and online resources that can provide more information and support
• how COPD will affect other long term conditions that are common in people with COPD (for example hypertension, heart disease, anxiety, depression, and musculoskeletal problems).
Evidence shows that self management plans, particularly when they include an exacerbation action plan, improve quality of life and reduce hospital admissions. Self management should include an individualised exacerbation action plan for any patient who is at risk of exacerbations with short (five day) courses of oral corticosteroids and oral antibiotics.
• Offer people a short course of oral corticosteroids and a short course of oral antibiotics to keep at home as part of their exacerbation action plan if -they have had an exacerbation within the last year, and remain at risk of exacerbations -they understand and are confident about when and how to take these medicines, and the associated benefits and harms -they know to tell their healthcare professional when they have used the medicines, and to ask for replacements.
[Based on very low to high quality evidence from randomised controlled trials and directly applicable health economic evidence]
• For acute exacerbations of COPD, prescribe a five day course of oral antibiotics (if indicated) and a five day course of 30 mg oral prednisolone. Consult the COPD antimicrobial prescribing guideline for factors to consider before prescribing antibiotics (box 4).
• At all review appointments, discuss corticosteroid and antibiotic use with people who keep these medicines at home, to check that they still understand how to use them. For people who have used three or more courses of oral corticosteroids and/or oral antibiotics in the last year, investigate the possible reasons for this. [Based on the experience and opinion of the Guideline Committee (GC)]
• Ask people with COPD if they experience breathlessness they find frightening. • Consider prescribing an antibiotic only after taking into account: -the severity of symptoms, particularly sputum colour changes and increases in sputum volume or thickness beyond the person's normal day-to-day variation -whether the person needs to go into hospital for treatment; previous exacerbation and hospital admission history, and the risk of developing complications -previous sputum culture and susceptibility results; and the risk of antimicrobial resistance with repeated courses of antibiotics
• Give oral antibiotics first line if the person can take oral medicines, and the severity of their exacerbation does not require intravenous antibiotics (see table 1 in guideline for choice of antibiotic, dose, and course length)
• Refer people to hospital if they have any signs or symptoms suggesting a more serious illness or condition such as cardiorespiratory failure or sepsis.
Identifying and managing anxiety and depression
Be alert for anxiety and depression in people with COPD. Long acting inhaled therapies are intended to improve day-to-day symptoms and reduce exacerbation risk. Before starting a long acting inhaled therapy, consider whether non-pharmacological COPD management has been optimised and vaccinations offered, if the person has been offered treatment for tobacco dependence if they smoke, and if they remain breathless or have exacerbations despite using a short acting bronchodilator. In addition, examine whether the person's day-to-day symptoms or acute episodes of worsening symptoms are caused by COPD and not by another physical or mental health condition. In particular, cardiac comorbidities, which may also cause breathlessness, are common and often underdiagnosed and undertreated in people with COPD. 5 6 If the person with COPD remains breathless or has exacerbations despite the above, then offer long acting anti-muscarinic (LAMA)+a long acting β 2 agonist (LABA) if they do not have asthmatic features or features suggesting steroid responsiveness (see below). A combination of LAMA+LABA is the most effective inhaled therapy. LAMA alone is superior to LABA alone, but economic modelling confirms that an initial combination dual bronchodilation strategy is superior to starting one agent and then adding another subsequently. The guideline recommends clinicians should minimise the number of inhalers and the number of different types of inhaler used by each person as far as possible.
People with a diagnosis of asthma and COPD should receive inhaled corticosteroids (ICS) and appropriate additional asthma therapies according to the NICE asthma guideline. 11 The guidelines acknowledge the difficulty of precisely delineating asthma from COPD in some individuals and the fact that this type of patient has in general been excluded from trials of inhaled therapy in COPD.
The following are defined as "asthmatic features/features suggesting steroid responsiveness":
• any previous, secure diagnosis of asthma or of atopy • a higher blood eosinophil count
• substantial variation in FEV 1 over time (at least 400 mL) or • substantial diurnal variation in peak expiratory flow (at least 20%).
"Higher" eosinophil count has been chosen deliberately, rather than specifying a particular value. Firstly, although evidence suggests a link between eosinophil count and steroid responsiveness, it is not yet clear what the precise threshold should be or on how many occasions or over what time period it should be elevated. Secondly, the term "higher" reflects the fact that the likely threshold is within the normal range of eosinophil counts, but in the upper range. 
Prophylactic antibiotics in people with frequent exacerbations
Regular antibiotic therapy can be beneficial in some people with COPD with frequent exacerbations, however it should only be considered in people with a substantial exacerbation burden and after several criteria have been met. Offer the "five fundamentals" of COPD care and treatment with inhaled therapies first.
• Before starting prophylactic antibiotic therapy in a person with COPD, think about whether respiratory specialist input is needed. [Based on the experience and opinion of the GC]
• Before offering prophylactic antibiotics, ensure that the person has had -sputum culture and sensitivity (including tuberculosis culture), to identify other possible causes of persistent or recurrent infection that may need specific treatment (eg, antibiotic resistant organisms, atypical mycobacteria, or No long term studies exist on the use of prophylactic antibiotics in people with COPD, therefore there may be some unknown risks or benefits related to their use in this manner for people with COPD. Prescribers and people with COPD should consider the wider antibiotic stewardship agenda and the risk of increasing antimicrobial resistance. Treatment should be reviewed after three months, and then at least every six months and only continued if the benefits outweigh the risks.
• For people who are taking prophylactic azithromycin and are still at risk of exacerbations, provide a non-macrolide antibiotic to keep at home as part of their exacerbation action plan (see recommendation 1.
on the NICE website). [Based on the experience and opinion of the GC]
Be aware that prophylactic azithromycin can be continued while another antibiotic is added if necessary for the treatment of an acute exacerbation of COPD.
Lung volume reduction
Lung volume reduction (LVR) surgery can improve breathlessness, exercise capacity, and survival in appropriately selected people with COPD with emphysema. 4 Evidence also supports the use of endobronchial valves in people with COPD who have intact interlobar fissures on computed tomography scan 7 8 (box 5). Other new recommendations provide information about when to refer people with COPD for lung transplantation surgery, but it is important that there is an absence of frailty or major comorbidities that could preclude a good outcome from surgery.
Box 5: When to refer for LVR procedures for COPD (surgery or endobronchial valve placement)
At the end of pulmonary rehabilitation, a person with COPD's condition should have been optimised as far as is going to be possible.
At this point, and at subsequent clinical reviews: 1.Think about whether LVR is a possible intervention if the following criteria are met:
• FEV 1 <50%
• limited by breathlessness (typically MRC breathlessness score of 4 or 5)
• person does not smoke 
Implementation
The measures set out in this guideline require comprehensive provision of treatment and support to stop smoking by smoking cessation teams and all clinicians caring for people with COPD across primary and secondary care. They also require provision and access to pulmonary rehabilitation in all patients limited by breathlessness, as well as addressing the large numbers of people with COPD (around 300 000 in England and Wales in 2018 9 ) who are not receiving flu vaccination.
Accurate diagnosis requires access to quality assured spirometry. Respiratory reviews should be structured to include assessment of relevant comorbidities, as multimorbidity is the norm rather than the exception in COPD. 5 Active review of inhaled therapy is needed and, in particular, the reason why people with COPD are taking inhaled corticosteroids should be accessible.
Access to LVR procedures is limited in the UK, representing a substantial unmet need. Pulmonary rehabilitation pathways will need to incorporate routine assessment for possible onward respiratory review in people who are still limited by breathlessness at the end of the programme to see if they may be eligible.
Guidelines into practice
• How do you ensure that all patients with COPD get systematic access to treatment and support to stop smoking, pulmonary rehabilitation, flu vaccination, self management advice, and psychological support?
• How do you ensure that patients with COPD are on the correct inhaled medication and know how to use it correctly?
• What system do you have in place to review patients who are using rescue packs of antibiotics and corticosteroids for frequent exacerbations?
How patients were involved in the creation of this article
Committee members involved in this guideline update included lay members who contributed to the formulation of the recommendations summarised here.
Future research
The guideline committee prioritised the following research recommendations: A Guideline Committee was established by the GUT, which incorporated healthcare and allied healthcare professionals (one respiratory physiotherapist, one respiratory nurse specialist, two consultant respiratory physicians, two general practitioners, and two senior pharmacists) and three lay members. The co-opted committee members consisted of one clinical psychologist, one consultant respiratory and transplant physician, one clinical scientist, and thoracic surgeon and one consultant radiologist.
The Committee were involved in scoping the 2018 update and agreeing the protocols for the 2018 and 2019 updates. The Committee reviewed the clinical evidence that had been identified and analysed by GUT using standard systematic review methodology. The clinical evidence was assessed for quality using GRADE methodology (www.gradeworkinggroup.org/) or modified GRADE methodology in the case of the diagnostic and prognostic review questions. They also examined the cost effectiveness of interventions where possible, including the use of a novel economic model that was generated for the 2018 inhaled therapy review and modified for the 2019 triple therapy review.
The 2017 scope and 2018/2019 updates went through public consultations where comments from stakeholder organisations were solicited, reviewed by the committee and NICE technical teams (NICE guideline scoping team and GUT) and incorporated into the final scope and guideline versions where appropriate.
The evidence reviewed in the 2018 and 2019 updates is available as separate review documents, while the evidence for the sections of the guideline that were not updated is contained in the June 2010 full guideline document. The guideline itself contains the recommendations with a new section on the rationale for the 2018 and 2019 recommendations. The documents are all available at https://www.nice.org.uk/guidance/ng115. 
